Aaron Gerds, MD, MS, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, comments on the rationale and results of a subgroup analysis of the Phase III MOMENTUM study evaluating the safety and efficacy of momelotinib vs danazol in thrombocytopenic patients with myelofibrosis (MF) (NCT04173494). In comparison to other JAK inhibitors, momelotinib suppresses both the JAK/STAT pathway and ALK2, which results in improvements in spleen volume response, symptom burden, as well as improvements in anemia response. The study showed that thrombocytopenic patients experienced the same benefit in spleen volume response, symptom burden, and anemia response as other patients with MF from MOMENTUM. The data from this study is expected to lead to the approval of momelotinib in MF. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
